| M&A Sellside | 1834 | Business Services | Logistics SaaS Company/Project Quarry | US | "Quarry" is a leader in its segment, with multiple product offerings, attractive historical growth, and the opportunity to accelerate that growth through pricing, new product introductions and entry into adjacent segments. | Revs 2021F $12M
EBITDA 2021F $3M |
| Capital Raise Equity | 1822 | Healthcare | Pharmaceutical Company/Project Forest | Northeast | Crossover financing for patented erectile dysfunction therapeutic approved for sale in Europe; funding for marketing and FDA 505(b)2 pathway. | $7 billion market; projecting $700M in sales by 2025 |
| Capital Raise Equity | 1785 | Natural Resources | Water Environmental Technologies & Solutions/Project Firstie | Northeast | Deploying proven, cost-effective solutions at the intersection of wastewater, resource recovery and renewable energy efficiency. | Excellent management, rapid growth, proactive organic & inorganic strategic initiatives. |
| Capital Raise Equity | 1795 | Healthcare | Drug Delivery Medical Device/Project Speedy | Northeast | Ultrasonic drug delivery medical device enabling proven drugs to address new indications. Funding 2-3 year expected 505(b)2 regulatory/clinical pathway. Initial focus - repurposing proven antibiotics to address complex infected wounds. | Demonstrated 100% success rate in 160+ pre-clinical patient procedures. No adverse effects. 20 limbs saved from amputation. |
| Capital Raise Equity | 1779 | Healthcare | Trauma Therapeutic/Project Turret | Northeast | Infusible oxygen carrier for field treatment of hemorrhagic shock. | $10M in US Army funding to date. |
| Capital Raise Equity | 1778 | Healthcare | Telemedicine Platform/Project Saturn | Southwest | Telemedicine software platform deployed by global insurance providers. | 5 million people covered by the platform. |
| Capital Raise Equity | 1774 | Healthcare | Wound Healing Therapeutic/Project Tamiami | South | Anhydrous treatment for chronic wounds that stimulates stem cells and increases blood supply for tissue regeneration. Delivery is enabled by telemedicine platform. | Marquee board and management team (J&J, P&G, Wyeth) |
| M&A Sellside | 1761 | Natural Resources | Specialty Chemicals: Super High Purity Alumina/Project Cavitate | Northeast | Proprietary ultrasonic/chemical technological process with disruptive economic & environmental benefits. Converts commodity aluminum into high-value high purity alumina (critical material to make synthetic sapphire). Economic value in hydrogen by-product. | Demonstrated production. End markets include semiconductors, Li-ion batteries, LEDs, biomedical and electronics devices. |
| M&A Sellside | 1758 | Healthcare | Chain of Body Contouring/Liposuction Centers/Project Belvedere | West | Thriving chain of body contouring/liposuction centers in high potential markets. 100% private pay. Fees collected in advance. | TTM Adj. EBITDA = $11.2M
2021F EBITDA = $15.3M |
| Capital Raise Debt | 1717 | Technology / Media / Telecom | Telecommunications Software Developer/Project LaSalle | Midwest | Company embeds software on phones to provide useful information about callers and to block spam and deliver marketing medium for businesses. | Partnered with Qualcomm |
| M&A Sellside | 1615 | Technology / Media / Telecom | Multi-Dwelling Unit Broadband Provider/Project Bandwidth | Midwest | Provider of broadband and cable to multi-dwelling units across six states in the Midwest. Contract with building owners, not end users. Some bulk. Low churn. Long term contracts. | 2020 Adj. EBITDA = $1.4M
9,200 passings,
8,700 RGUs
$52.57 ARPU |
| Capital Raise Equity | 1605 | Healthcare | Semiconductor and Electronics Manufacturer/Project Milliard | Midwest | Advanced product authentication technology for logistics and anti-counterfeiting measures. Compatible with blockchain and Internet of Things. | Potential for EBITDA > $100M over the next several years |
